GlaxoSmithKline has acquired a shuttered vaccine plant in the Philadelphia area and plans to invest $100 million in the 90-acre site. GSK says it will hire 300 people to reopen the plant, which will help solidify Philadelphia's reputation as the vaccine capital of the nation. GSK bought the vaccine facility from Wyeth. GSK plans to use the site to begin work with a new technology that makes vaccines from cell cultures, a faster approach than using chicken eggs in the traditional method of vaccine manufacturing.
- read this report from the Philadelphia Inquirer for more